Prelude Capital Management’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $299K | Sell |
551
-1,794
| -77% | -$1.01M | 0.02% | 780 |
|
|
2026
Q1 | $1.39M | Sell |
2,345
-1,415
| -38% | -$705K | 0.11% | 230 |
|
|
2025
Q4 | $1.83M | Buy |
3,760
+946
| +34% | +$441K | 0.13% | 167 |
|
|
2025
Q3 | $1.18M | Buy |
+2,814
| New | +$946K | 0.09% | 276 |
|
|
2023
Q4 | – | Sell |
-6,415
| Closed | -$1.45M | – | 1359 |
|
|
2023
Q3 | $1.45M | Buy |
+6,415
| New | +$1.48M | 0.09% | 244 |
|
|
2021
Q3 | – | Sell |
-33,635
| Closed | -$6.03M | – | 2037 |
|
|
2021
Q2 | $6.03M | Buy |
33,635
+11,160
| +50% | +$2.13M | 0.18% | 76 |
|
|
2021
Q1 | $3.76M | Buy |
22,475
+615
| +3% | +$103K | 0.1% | 148 |
|
|
2020
Q4 | $3.32M | Buy |
21,860
+20,998
| +2,436% | +$2.76M | 0.08% | 175 |
|
|
2020
Q3 | $87K | Sell |
862
-3,318
| -79% | -$364K | ﹤0.01% | 959 |
|
|
2020
Q2 | $506K | Buy |
+4,180
| New | +$470K | 0.03% | 474 |
|
|
2019
Q3 | – | Sell |
-222
| Closed | -$17K | – | 2063 |
|
|
2019
Q2 | $17K | Buy |
+222
| New | +$20.8K | ﹤0.01% | 1318 |
|
|
2017
Q4 | – | Sell |
-2,406
| Closed | -$282K | – | 1739 |
|
|
2017
Q3 | $282K | Buy |
+2,406
| New | +$307K | 0.03% | 535 |
|
|
2017
Q1 | – | Sell |
-2,888
| Closed | -$414K | – | 1791 |
|
|
2016
Q4 | $414K | Buy |
+2,888
| New | +$369K | 0.05% | 353 |
|
|
2016
Q3 | – | Sell |
-1,981
| Closed | -$210K | – | 1832 |
|
|
2016
Q2 | $210K | Sell |
1,981
-4,504
| -69% | -$502K | 0.03% | 480 |
|
|
2016
Q1 | $723K | Sell |
6,485
-708
| -10% | -$89.6K | 0.1% | 222 |
|
|
2015
Q4 | $1.13M | Buy |
7,193
+4,345
| +153% | +$633K | 0.17% | 143 |
|
|
2015
Q3 | $374K | Sell |
2,848
-559
| -16% | -$89.7K | 0.05% | 356 |
|
|
2015
Q2 | $593K | Sell |
3,407
-640
| -16% | -$115K | 0.08% | 274 |
|
|
2015
Q1 | $698K | Sell |
4,047
-334
| -8% | -$50.9K | 0.1% | 254 |
|
|
2014
Q4 | $567K | Sell |
4,381
-1,927
| -31% | -$248K | 0.08% | 275 |
|
|
2014
Q3 | $812K | Buy |
6,308
+674
| +12% | +$69.5K | 0.11% | 218 |
|
|
2014
Q2 | $499K | Sell |
5,634
-2,098
| -27% | -$202K | 0.07% | 381 |
|
|
2014
Q1 | $727K | Buy |
7,732
+1,856
| +32% | +$190K | 0.1% | 282 |
|
|
2013
Q4 | $664K | Buy |
5,876
+1,780
| +43% | +$161K | 0.11% | 259 |
|
|
2013
Q3 | $323K | Sell |
4,096
-8,257
| -67% | -$604K | 0.05% | 398 |
|
|
2013
Q2 | $813K | Buy |
+12,353
| New | +$796K | 0.17% | 139 |
|
Other funds holding UTHR
ACA
JT
Prelude Capital Management's UTHR Position: Q2 2026 in Review
Prelude Capital Management reduced its United Therapeutics (UTHR) stake by 77% in Q2 2026, selling an estimated $1.01M and leaving 551 shares worth $299K. The position accounts for 0.02% of the portfolio, ranked #780.
Prelude Capital Management first reported a position in UTHR in Q2 2013 and has held it in 26 quarters since. The position peaked at $6.03M in Q2 2021. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.
- Prelude Capital Management held 551 shares of United Therapeutics worth $299K as of Q2 2026.
- Prelude Capital Management sold 1,794 United Therapeutics shares in Q2 2026, an estimated $1.01M.
- United Therapeutics made up 0.02% of Prelude Capital Management's portfolio in Q2 2026, its #780 holding.
- Prelude Capital Management first reported a position in United Therapeutics in Q2 2013 and has held it in 26 quarters since.
- Prelude Capital Management's United Therapeutics position peaked at $6.03M in Q2 2021.
- 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.
Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.